Evidence map›Paper›PMID 40291011›Full record

ArticleLung Cancer (Auckland, N.Z.)2025

Prevalence of

Tu Van Dao, Van Luong Dinh, Thanh Vinh Doan, Tri Le Phuong

Abstract read
In one paragraph

Article in Lung Cancer (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tu Van Dao *Cancer Research and Clinical Trials Center, Department of Optimal Therapy, Vietnam National Cancer Hospital, Hanoi, Vietnam.
Van Luong Dinh *Lung Transplant Center, National Lung Hospital, Hanoi, Vietnam.
Thanh Vinh DoanOncology Department, Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam.
Tri Le PhuongMedical Affairs, AstraZeneca Vietnam, Ho Chi Minh City, Vietnam.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Comprehensive profiling of mutations in the Methods: We investigated the prevalence of Results: A total 200 patients (age: median [range], 60.0 [30.0-80.0] years) were enrolled from 3 centers; 56.0% were males and 64.0% never smoked. The prevalence of Conclusion: These results underscore the need for

Indexed as

early-stage resectable non-small cell lung cancerEGFRmepidermal growth factor receptor mutationstargeted therapiesVietnam

Identifiers

PMID40291011
PMCPMC12025828

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.